Novel Coronavirus (COVID-19) Pipeline Guide 2020: Therapeutics Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type
DUBLIN, July 8, 2020 /PRNewswire/ -- The "Coronavirus Disease 2019 (COVID-19) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This pipeline guide provides an overview of the Coronavirus Disease 2019 (COVID-19) (Infectious Disease) pipeline landscape.
The guide provides comprehensive information on the therapeutics under development for Coronavirus Disease 2019 (COVID-19) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The pipeline guide also reviews of key players involved in therapeutic development for Coronavirus Disease 2019 (COVID-19) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 15, 29, 34, 3, 30, 111, 164 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 6, 1, 1, 25 and 29 molecules, respectively.
The guide helps in identifying and tracking emerging players in the market and their portfolios enhance decision-making capabilities and help to create effective counter-strategies to gain competitive advantage.
Scope of the Guide
-- The pipeline guide provides a snapshot of the global therapeutic
landscape of Coronavirus Disease 2019 (COVID-19) (Infectious Disease).
-- The pipeline guide reviews pipeline therapeutics for Coronavirus Disease
2019 (COVID-19) (Infectious Disease) by companies and
universities/research institutes based on information derived from
company and industry-specific sources.
-- The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and undisclosed
stages.
-- The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing and
collaboration details, R&D brief, MoA & other developmental activities.
-- The pipeline guide reviews key companies involved in Coronavirus Disease
2019 (COVID-19) (Infectious Disease) therapeutics and enlists all their
major and minor projects.
-- The pipeline guide evaluates Coronavirus Disease 2019 (COVID-19)
(Infectious Disease) therapeutics based on mechanism of action (MoA),
drug target, route of administration (RoA) and molecule type.
-- The pipeline guide encapsulates all the dormant and discontinued
pipeline projects.
-- The pipeline guide reviews the latest news related to pipeline
therapeutics for Coronavirus Disease 2019 (COVID-19) (Infectious
Disease)
Key Topics Covered
1. Introduction
-- Report Coverage
-- Coronavirus Disease 2019 (COVID-19) - Overview
-- Coronavirus Disease 2019 (COVID-19) - Therapeutics Development
2. Pipeline Overview
-- Pipeline by Companies
-- Pipeline by Universities/Institutes
-- Products under Development by Companies
-- Products under Development by Universities/Institutes
3. Coronavirus Disease 2019 (COVID-19) - Therapeutics Assessment
-- Assessment by Target
-- Assessment by Mechanism of Action
-- Assessment by Route of Administration
-- Assessment by Molecule Type
4. Coronavirus Disease 2019 (COVID-19) - Companies Involved in Therapeutics Development
-- 4D Pharma PLC
-- A2A Pharmaceuticals Inc.
-- AbCellera Biologics Inc.
-- Adaptive Biotechnologies Corp.
-- AIM ImmunoTech Inc.
-- Akers Biosciences Inc.
-- Akston Biosciences Corp.
-- Aldeyra Therapeutics Inc.
-- Zucero Therapeutics Ltd.
5. Coronavirus Disease 2019 (COVID-19) - Drug Profiles
-- (ASC-09 + ritonavir) - Drug Profile
-- (emtricitabine + tenofovir disoproxil fumarate) - Drug Profile
-- acalabrutinib maleate - Drug Profile
-- ADX-629 - Drug Profile
-- AKS-446 - Drug Profile
-- AlloStim - Drug Profile
-- Ampion - Drug Profile
-- anakinra - Drug Profile
-- Antibodies 1 for Coronavirus Disease 2019 (COVID-19) - Drug Profile
-- Antibodies for Coronavirus Disease 2019 (COVID-19) - Drug Profile
-- Coronavirus Disease 2019 (COVID-19) - Product Development Milestones
6. Featured News & Press Releases
7. Appendix
8. Methodology
-- Coverage
-- Secondary Research
-- Primary Research
-- Expert Panel Validation
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8cpoqx
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
